SLGL
Sol-Gel Technologies Ltd (SLGL)
Healthcare • NASDAQ • $77.39-0.44%
- Symbol
- SLGL
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $77.39
- Daily Change
- -0.44%
- Market Cap
- $254.10M
- Trailing P/E
- N/A
- Forward P/E
- -10.09
- 52W High
- $97.97
- 52W Low
- $20.06
- Analyst Target
- $196.67
- Dividend Yield
- N/A
- Beta
- N/A
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorp…
Company websiteResearch SLGL on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.